Suzanne L Epstein

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. pmc DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice
    Suzanne L Epstein
    Food and Drug Administration, Rockville, Maryland 20852 1448, USA
    Emerg Infect Dis 8:796-801. 2002
  2. ncbi request reprint Control of influenza virus infection by immunity to conserved viral features
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, HFM 730, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, USA
    Expert Rev Anti Infect Ther 1:627-38. 2003
  3. ncbi request reprint Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
  4. ncbi request reprint Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    J Infect Dis 193:49-53. 2006
  5. doi request reprint Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
    Chia Yun Lo
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852 1448, USA
    Vaccine 26:2062-72. 2008
  6. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
  7. doi request reprint Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses
    Graeme E Price
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Vaccine 27:6512-21. 2009
  8. doi request reprint Genetic control of immune responses to influenza A matrix 2 protein (M2)
    Julia A Misplon
    Food and Drug Administration, Center for Biologics and Research, HFM 730, Rockville, MD 20852, USA
    Vaccine 28:5817-27. 2010
  9. pmc Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus
    Alessandra Vitelli
    Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 8:e55435. 2013
  10. pmc Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice
    Mark R Soboleski
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21937. 2011

Collaborators

Detail Information

Publications17

  1. pmc DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice
    Suzanne L Epstein
    Food and Drug Administration, Rockville, Maryland 20852 1448, USA
    Emerg Infect Dis 8:796-801. 2002
    ..In the absence of antigenically matched hemagglutinin-based vaccines, DNA vaccination with conserved influenza genes may provide a useful first line of defense against a rapidly spreading pandemic virus...
  2. ncbi request reprint Control of influenza virus infection by immunity to conserved viral features
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, HFM 730, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, USA
    Expert Rev Anti Infect Ther 1:627-38. 2003
    ..How does cross-protection work in animals, and can we apply what we have learned about it to induce broad cross-protection in humans?..
  3. ncbi request reprint Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
    ..Thus, gene-based vaccination with NP may contribute to protective immunity against diverse influenza viruses through its ability to stimulate cellular immunity...
  4. ncbi request reprint Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    J Infect Dis 193:49-53. 2006
    ..These findings suggest an impact of accumulated heterosubtypic immunity during a pandemic. Such immunity, as well as its implications for vaccination, should be further investigated...
  5. doi request reprint Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
    Chia Yun Lo
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852 1448, USA
    Vaccine 26:2062-72. 2008
    ..Existing ca vaccines may provide some Het-I, but experimental vaccination focusing on conserved antigens was more effective in this model for protection against a divergent, highly pathogenic virus...
  6. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A...
  7. doi request reprint Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses
    Graeme E Price
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Vaccine 27:6512-21. 2009
    ..These findings demonstrate potent protection by vaccination highly focused on conserved antigens and identify immune response measures in mice that differed among vaccinations and correlated with outcome...
  8. doi request reprint Genetic control of immune responses to influenza A matrix 2 protein (M2)
    Julia A Misplon
    Food and Drug Administration, Center for Biologics and Research, HFM 730, Rockville, MD 20852, USA
    Vaccine 28:5817-27. 2010
    ..The conjugate vaccine enhanced some outcomes but not others. Co-immunizing with NP improved outcomes over either NP or M2 immunizations alone. These results have implications for vaccination of genetically diverse populations...
  9. pmc Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus
    Alessandra Vitelli
    Gene Therapy and Immunogenicity Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 8:e55435. 2013
    ..Thus PanAd3 is a promising candidate vector for vaccines, including universal influenza vaccines...
  10. pmc Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice
    Mark R Soboleski
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21937. 2011
    ..Here we test two prototype vaccines for cross-protection against the recent pandemic virus...
  11. pmc Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model
    Graeme E Price
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA
    J Virol 88:6019-30. 2014
    ....
  12. pmc Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response
    Kathrina Quinn
    Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:1990-8. 2011
    ..Our findings suggest further evaluation of AAV12 as a vector for gene therapy and as a potential nasal vaccine...
  13. pmc Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses
    Graeme E Price
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, United States of America
    PLoS ONE 5:e13162. 2010
    ..Here we evaluate a single dose universal vaccine strategy using recombinant adenoviruses (rAd) expressing the conserved influenza virus antigens matrix 2 and nucleoprotein...
  14. pmc Protection against lethal influenza virus challenge by RNA interference in vivo
    Stephen Mark Tompkins
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8682-6. 2004
    ..These results indicate that RNA interference is promising for control of influenza virus infection, as well as other viral infections...
  15. ncbi request reprint Critical path workshop on the development of cellular and gene therapy products
    Eda T Bloom
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Mol Ther 12:5-8. 2005
  16. pmc TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection
    Ivett Jelinek
    Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:2422-9. 2011
    ..These results provide the basis for the development of TLR3-specific adjuvants capable of inducing immune responses tailored for viral pathogens...
  17. doi request reprint Cross-protective immunity to influenza A viruses
    Suzanne L Epstein
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Expert Rev Vaccines 9:1325-41. 2010
    ..These vaccines could be used 'off the shelf' early in an outbreak or pandemic, before strain-matched vaccines are available...